<DOC>
	<DOCNO>NCT01579526</DOCNO>
	<brief_summary>The purpose study determine safety pharmacokinetics FP01 healthy volunteer .</brief_summary>
	<brief_title>A Single Dose Study Determine Safety Pharmacokinetics FP01 Lozenges Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA 1 . Subjects male female volunteer 18 55 year age inclusive . 2 . BMI 18 30 , inclusive . 3 . Subjects must estimate creatinine clearance rate ≥ 80 mL/min determine CockcroftGault equation ( see section 7.1 ) . 4 . Female subject childbearing potential must use adequate birth control determine Investigator . 5 . Female subject childbearing potential must negative pregnancy test result screen Day 1 . 6 . Subjects must able provide inform consent risk benefit explain . 7 . Subjects must nonsmoking nontobacco user ( define subject smoke use tobacco product ≥ 12 month study screen ) , must agree abstain alcohol caffeine 72 hour prior study dose participation study . 8 . Subjects must 12 lead ECG without clinically significant abnormality rate , rhythm , interval conduction , determine Investigator . 9 . Subjects generally good health , base prestudy medical history , physical examination routine laboratory test , determine Investigator . 10 . Subjects clinically significant disease and/or clinically significant abnormal laboratory value determine Investigator base medical history , physical examination , laboratory evaluation conduct screen visit admission clinic . 11 . Be willing able comply study protocol requirement duration study , include pharmacokinetic sampling EXCLUSION CRITERIA 1 . Females pregnant lactating . 2 . Subjects history drug alcohol abuse within 12 month study screening , determine Investigator . 3 . Subjects participate investigational trial within 30 day six halflives test drug 's biologic activity , whichever longer , start study ( time first dose ) . 4 . Subjects clinically significant medical psychiatric illness currently within 30 day start study ( time first dose ) , determine Investigator . 5 . Subjects oral lesion observe screening visit Day 1 visit . 6 . Subjects history significant allergy ( include history asthma , food , drug allergy ) , determine Investigator . 7 . Subjects significant blood loss , donate receive one pint blood within 30 day prior dose . 8 . Subjects symptoms significant acute illness include upper respiratory infection within 30 day prior start study ( time first dose ) , determine Investigator . 9 . Subjects condition interfere ability understand comply requirement study . 10 . Subjects positive drug screen alcohol screen study screen Day 1 . 11 . Subjects disease condition ( medical surgical ) might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , central nervous system function ; condition might interfere absorption , distribution , metabolism , excretion study drug , would place subject increase risk , determine Investigator . 12 . Subjects positive result screen HIV , Hepatitis B , Hepatitis C. 13 . Subjects receive concomitant prescription , overthecounter , herbal medication 7 day prior study dose , exception hormonal contraceptive 3 dos acetaminophen dose 1 gram less time study screen time study dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Safety Pharmacokinetics FP01 Healthy Volunteers</keyword>
</DOC>